HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yoshihiro Ogawa Selected Research

ipragliflozin

7/2021Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
1/2019Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
8/2017Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
1/2016Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yoshihiro Ogawa Research Topics

Disease

51Obesity
11/2023 - 01/2002
45Neoplasms (Cancer)
05/2024 - 01/2002
34Inflammation (Inflammations)
11/2023 - 10/2005
33Hyperaldosteronism (Conn Syndrome)
03/2024 - 12/2015
23Insulin Resistance
05/2023 - 01/2002
20Adenoma (Adenomas)
03/2024 - 08/2015
18Type 2 Diabetes Mellitus (MODY)
03/2024 - 09/2003
15Fibrosis (Cirrhosis)
11/2023 - 10/2003
13Non-alcoholic Fatty Liver Disease
11/2023 - 11/2011
12Hypertension (High Blood Pressure)
03/2024 - 09/2000
12Body Weight (Weight, Body)
10/2021 - 01/2002
11Pancreatic Neoplasms (Pancreatic Cancer)
08/2023 - 01/2006
11Hyperglycemia
01/2023 - 09/2003
10Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2018 - 01/2007
9Cushing Syndrome
09/2023 - 05/2014
8Hemorrhage
03/2024 - 01/2002
8Diabetes Mellitus
02/2022 - 01/2015
8Esophageal Neoplasms (Esophageal Cancer)
04/2010 - 08/2002
7Neoplasm Metastasis (Metastasis)
05/2024 - 03/2006
7Neuroendocrine Tumors (Neuroendocrine Tumor)
02/2024 - 06/2017
7Dyslipidemias (Dyslipidemia)
10/2021 - 11/2011
7Hepatocellular Carcinoma (Hepatoma)
01/2021 - 11/2011
6Liver Cirrhosis (Hepatic Cirrhosis)
11/2023 - 01/2015
6Hypokalemia
05/2023 - 05/2014
6Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 11/2009
6Hypertrophy
07/2021 - 09/2000
6Carcinoma (Carcinomatosis)
01/2020 - 09/2002
6Hypoglycemia (Reactive Hypoglycemia)
01/2020 - 09/2002
5Esophageal Achalasia (Megaesophagus)
03/2024 - 01/2018
5Stomach Neoplasms (Stomach Cancer)
01/2024 - 02/2018
4Osteoporosis
09/2023 - 01/2021
4Liver Diseases (Liver Disease)
01/2023 - 01/2016
4Hyperinsulinism (Hyperinsulinemia)
01/2023 - 09/2003
4Diabetic Nephropathies (Diabetic Nephropathy)
01/2022 - 01/2005
4Starvation
01/2022 - 03/2010
4Fatty Liver
01/2021 - 11/2011
4Alcoholic Fatty Liver
01/2021 - 01/2015
4Edema (Dropsy)
05/2014 - 03/2003
3Vascular Diseases (Vascular Disease)
11/2023 - 05/2009
3Atherosclerosis
11/2023 - 11/2017
3Acute Liver Failure (Fulminant Hepatic Failure)
11/2023 - 01/2022
3Disease Progression
08/2023 - 04/2010
3Autoimmune Pancreatitis
01/2023 - 09/2018
3Sarcopenia
11/2022 - 01/2017
3Pathologic Constriction (Stenosis)
01/2022 - 12/2018
3Hypoxia (Hypoxemia)
01/2022 - 06/2021
3Cholangiocarcinoma
01/2022 - 11/2011
3Diabetic Retinopathy (Retinopathy, Diabetic)
11/2021 - 09/2004

Drug/Important Bio-Agent (IBA)

31AldosteroneIBA
03/2024 - 08/2015
27Glucose (Dextrose)FDA LinkGeneric
01/2023 - 01/2002
19Hydrocortisone (Cortisol)FDA LinkGeneric
03/2024 - 01/2012
19LeptinIBA
01/2023 - 01/2002
14Insulin (Novolin)FDA Link
01/2020 - 01/2002
12Adrenocorticotropic Hormone (ACTH)FDA Link
03/2024 - 01/2012
12Sodium-Glucose Transporter 2 InhibitorsIBA
11/2023 - 01/2016
12EnzymesIBA
05/2023 - 05/2007
11Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA
11/2023 - 01/2002
11Fatty Acids (Saturated Fatty Acids)IBA
01/2023 - 07/2009
11Triglycerides (Triacylglycerol)IBA
01/2021 - 04/2003
10LipidsIBA
11/2023 - 04/2005
10Biomarkers (Surrogate Marker)IBA
11/2021 - 11/2011
8Proteins (Proteins, Gene)FDA Link
03/2024 - 12/2009
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2023 - 10/2005
8AdipokinesIBA
01/2019 - 09/2007
8Eicosapentaenoic AcidIBA
01/2015 - 01/2007
7CytokinesIBA
03/2024 - 11/2006
7Messenger RNA (mRNA)IBA
01/2022 - 01/2007
6RNA (Ribonucleic Acid)IBA
04/2024 - 11/2002
6Hormones (Hormone)IBA
01/2024 - 09/2000
6ReninIBA
12/2022 - 01/2019
6Transcription Factors (Transcription Factor)IBA
11/2022 - 03/2010
6LigandsIBA
11/2020 - 06/2008
5SteroidsIBA
03/2024 - 12/2005
5CholesterolIBA
11/2023 - 10/2008
5SodiumIBA
02/2022 - 01/2017
5Antihypertensive Agents (Antihypertensives)IBA
01/2022 - 01/2016
5BilirubinIBA
01/2022 - 02/2018
5Sodium-Glucose Transport ProteinsIBA
10/2021 - 01/2019
4Streptozocin (Streptozotocin)FDA Link
02/2024 - 03/2013
4GlucocorticoidsIBA
12/2022 - 01/2014
4Fluorouracil (Carac)FDA LinkGeneric
08/2022 - 02/2003
4Mineralocorticoid Receptor AntagonistsIBA
01/2022 - 01/2019
4Cytochrome P-450 CYP11B2 (CYP11B2)IBA
01/2022 - 08/2015
4ipragliflozinIBA
07/2021 - 01/2016
4DNA (Deoxyribonucleic Acid)IBA
01/2018 - 11/2007
4Brain Natriuretic Peptide (Natrecor)FDA Link
12/2007 - 09/2000
3Hemostatics (Antihemorrhagics)IBA
01/2024 - 01/2018
3Angiotensin IIIBA
11/2023 - 12/2001
3AndrogensIBA
09/2023 - 05/2009
3Indicators and Reagents (Reagents)IBA
11/2022 - 10/2008
3InterleukinsIBA
11/2021 - 01/2015

Therapy/Procedure

29Therapeutics
05/2024 - 01/2002
28Radiotherapy
07/2012 - 01/2002
13Adrenalectomy
01/2022 - 01/2018
11Drug Therapy (Chemotherapy)
02/2024 - 07/2005
5Traction
01/2024 - 01/2020
4Stents
12/2023 - 01/2020
4Aftercare (After-Treatment)
08/2020 - 04/2003
3Surgical Instruments (Clip)
01/2024 - 02/2018
3Hematopoietic Stem Cell Transplantation
03/2023 - 02/2020